Expert Solutions for Oligonucleotide Discovery, Development, and Analysis
Oligonucleotides are an emerging therapeutic option to target a wide range of hard-to-treat diseases, particularly those caused by genetic mutations. Several oligonucleotide drugs have been licensed in recent years, and many others are currently in different phases of drug development.
Altasciences has expertise in the development of highly sensitive bioanalytical assays for the quantitation of oligonucleotides in complex biological matrices such as eye, liver, or brain tissue, adapted to the different critical parameters of your preclinical and clinical studies.
Comprehensive Support for Oligonucleotide Development
From preclinical to clinical, our laboratory scientific experts support robust and sensitive bioanalytical assays that minimize interference for accurate oligonucleotide bioanalysis and quantification.
Beyond the core analytical techniques, Altasciences provides various services to support the oligonucleotide development journey.
- Immunogenicity Testing: We offer immunogenicity/anti-drug antibody assay development and validation to assess the potential immune response to oligonucleotide therapies.
- PCR Analysis: Our expertise extends to various PCR techniques, including real-time PCR and dPCR, for sensitive and specific detection of oligonucleotide sequences.
- Tissue-Based Analysis: We have the capabilities to perform tissue-based analysis, enabling the quantification and characterization of oligonucleotides in target tissues.
- Regulatory Guidance: Our team provides expert guidance on navigating the complex regulatory landscape for oligonucleotides and other cell and gene therapies, ensuring compliance and facilitating successful development programs.
years’ working knowledge
preclinical and clinical studies conducted at various stages
samples analyzed in oligonucleotide quantitation
bioanalytical techniques and platforms for oligonucleotides:
- Meso Scale Discovery (MSD™) multiplexing technology utilizing the electroluminescence-based detection system
- Mass spectrometry-based quantification of linear and conjugated oligos (ASO, siRNA, aptamer) using solid phase extraction (SPE) or automated hybridization LC-MS/MS workflow
- In vitro plasma stability, metabolite identification, and plasma protein binding studies using mass spectrometry platforms
- Technology selection advice based upon sensitivity, selectivity, complexity, dynamic range, throughput and specific program needs
Related Resources
-
Presentation—Strategies to Improve Assay Sensitivity to Quantify Therapeutic Oligonucleotides -
Presentation—Sensitive Quantitation of ASOs -
Research Article—Method for Quantifying ASOs in Mouse Serum -
The Altascientist—Quantification of ASOs -
eBook: ASOs—Expert Interviews, Case Studies, and More! -
Overview of LBA and LC–MS/MS analysis of ASOs -
Poster: Dev. of a Surrogate CSF Matrix for Quantitative Analysis of ASOs
Learn more about our laboratory services
Click below to explore more of Altasciences’ bioanalytical solutions.
THERAPEUTIC AREAS
Our deep expertise and capabilities in a broad range of therapeutic areas encompasses preclinical and early clinical studies for both small molecules and biologics. We can manage your entire program, as well as provide comprehensive support research services and bioanalytical expertise.